A case of primary non-Hodgkin's lymphoma of the uterine cervix treated by combination chemotherapy (THP-COP)

J Obstet Gynaecol Res. 1998 Apr;24(2):157-60. doi: 10.1111/j.1447-0756.1998.tb00068.x.

Abstract

We present a case of primary non-Hodgkin's lymphoma of the uterine cervix, Ann Arbor stage IE. This 64-year-old multiparous Japanese woman showed markedly elevated serum levels of lactate dehydrogenase (LDH) and of soluble interleukin-2 receptor (sIL-2R) at the time of diagnosis. Combination chemotherapy was administered and consisted of pirarubicin, cyclophosphamide, vincristine sulfate, and prednisolone (THP-COP). After 3 courses of such therapy, the serum levels of LDH and of sIL-2R decreased within normal limits, and the patient achieved a complete remission.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cervix Uteri / pathology
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Doxorubicin / analogs & derivatives
  • Female
  • Humans
  • Immunohistochemistry
  • L-Lactate Dehydrogenase / blood
  • Lymphoma, Large B-Cell, Diffuse / diagnosis
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Magnetic Resonance Imaging
  • Middle Aged
  • Neoplasm Staging
  • Prednisolone / administration & dosage
  • Receptors, Interleukin-2 / blood
  • Remission Induction
  • Uterine Cervical Neoplasms / diagnosis
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / pathology
  • Vincristine / administration & dosage

Substances

  • Receptors, Interleukin-2
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone
  • L-Lactate Dehydrogenase

Supplementary concepts

  • VEP-THP protocol